NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch » TOP 50 Pharmas » Bayer  1    
found files: 14
Bayer »25/08/2007 [Company watch]
merger of the healthcare units of Bayer and Schering nears completion.

Bayer Schering Pharmaceuticals China expects to maintain growth of over 30 percent in the market, as the merger of the healthcare units of Bayer and Schering nears completion....   more»

Bayer »05/03/2008 [Company watch]
Bayer expects to be China's biggest drug seller within months

The Company's Asia unit said it expects to be China's biggest drug seler thanks to its treatments for diabetes and blood pressure. In 2007 sales in China grew 47% to $1.3billion making up about a third of its revenues in Asia (excluding Japan)....   more»

Bayer »24/06/2008 [Company watch]
Will Bayer AG Overtake AstraZeneca in China Drug Sales

According to Reuters, Germany's Bayer AG (BYERF.PK) thinks it can become the biggest seller of prescription drugs in China this year, bypassing AstraZeneca (NYSE: AZN), which is currently the top dog. Arthur J. Higgins, the head of Bayer Healthcare, said that revenues in China are growing at more than 40% annually. In 2008, they will top $500 million for the Germany-based pharma giant. Worldwide, Higgins expects Bayer will do some small deals this year, probably in medical devices, diabetes care, animal health and regional opportunities in over-the-counter medicines, but would most likely not undertake a mega-transaction, even though it has the capacity to do so. He also said that Bayer would not make a major purchase of a generic firm. It is currently doing quite well with its off-patent drugs in China, so a generic acquisition would not be helpful...   more»

Bayer »29/07/2008 [Company watch]
China approves Nexavar to treat liver cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, have said that the State Food and Drug Administration (SFDA) of China has approved Nexavar (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the first and only oral targeted therapy to significantly improve overall survival in patients with the disease. The approval was based on two international phase III double blind, placebo-controlled trials that evaluated more than 800 patients who received no prior systemic therapy. Dr Gunnar Riemann, member of the executive committee of Bayer HealthCare, said China has the highest number of liver cancer patients worldwide with more than 340,000 new cases diagnosed each year and the incidence is continuing to rise. We are proud to be at the forefront of liver cancer treatment with Nexavar and are hopeful that patients in China can potentially have their lives extended by treatment with Nexavar. “The approval in liver cancer in China comes less than two years after the approval in advanced kidney cancer and proves that Nexavar is and will continue to be an important foundational therapy in multiple patient populations,” said Dr N Anthony Coles, president and chief executive officer, Onyx Pharmaceuticals. Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. In the Asia-Pacific region, more than eight percent of the general population is infected with chronic hepatitis B and between two and four percent is infected with chronic hepatitis C. Both infections are the leading causes of primary liver cancer worldwide...   more»

Bayer »14/11/2008 [Company watch]
Bayer to develop hemophilia treatment centres in China

German-based pharmaceutical company, Bayer Schering , announced a $1.9 million pledge to develop Hemophilia Treatment Centers (HTCs) throughout China....   more»

Bayer »12/02/2009 [Company watch]
Bayer invests $129mn on Beijing R&D centre

Bayer Schering Pharma, the pharmaceutical division of Bayer HealthCare (BHC), will be strengthening its global Research and Development (R&D) capabilities through the foundation of a global R&D center in Beijing, China....   more»

Bayer »22/03/2009 [Company watch]
Bayer strikes R&D deal with Chinese university

Bayer has furthered its R&D expansion in China with an agreement to form a joint pharmaceutical research centre with Tsinghua University in Beijing....   more»

Bayer »28/03/2009 [Company watch]
Bayer eyes Bioton cooperation in China

German company Bayer is examining China-based production units of Polish insulin maker Bioton BOTN.WA as it is interested in cooperation between the two companies, daily Parkiet reported on Monday....   more»

Bayer »05/06/2009 [Company watch]
Bayer China Launches Country Carbon Footprint Project

Pioneering CO2 Emissions Control in the Chemical and Pharmaceutical Industry...   more»

Bayer »08/06/2009 [Company watch]
Sartorius Stedim Biotech Extends Portfolio In The Area Of Single-Use Bioreactors

Partnerships with Bayer Technology Services and ExcellGene Prototypes of new single-use bioreactors at the ACHEMA 2009...   more»

»01/07/2009 [Company watch]
Bayer Launches New Anti-Clotting Drug in China

Bayer Healthcare has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval....   more»

Bayer »07/12/2009 [Company watch]
Bayer Receives SFDA Approval For Betaferon To Treat Multiple Sclerosis

The Chinese State Food and Drug Administration (SFDA) has approved Bayer Schering Pharma\'s Betaferon (interferon beta-1b) therapy for patients with relapsing-remitting multiple sclerosis (MS). Bayer plans to launch Betaferon in China by mid 2010. Betaferon is available in more than 100 countries around the world....   more»

Bayer »18/02/2010 [Company watch]
Bayer Seeks Better Than 20% Growth in China

China’s dissemination of health care insurance throughout the country will power 20% annual growth in spending for medicines in the country, according to Liam Condon, who spearheaded Bayer AG’s (BAYRY.PK) operations in China until the end of 2009. Bayer [XETRA: BAY] itself expects to produce returns that beat the 20% rate of growth....   more»

Bayer »27/04/2010 [Company watch]
Bayer Reports $709 Million in 2009 China Revenues

Bayer AG (BAYRY.PK) said its China revenues in 2009 totaled $709 million, a 28% increase from the year earlier. This means the company met its yearly goal of beating the 20% growth of China’s pharma market last year. To help meet that target in the future, Bayer expects to introduce 20 new products over the next five years. The average of four new drugs per year is slightly better than 2009, when it completed three launches....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.